Conditions: Hypertension
Keywords: Clinical Trial Randomized Controlled Trial Humans Cyclic Nucleotide Phosphodiesterases Type 5
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 135
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: placebo intervention 2: PF-00489791 intervention 3: PF-00489791 intervention 4: PF-00489791
Intervention descriptions: intervention 1: placebo, oral, tablets, once daily, for 28 days intervention 2: PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days intervention 3: PF-00489791 4 mg, oral, tablets, once daily, for 28 days intervention 4: PF-00489791 10 mg, oral, tablets, once daily, for 28 days

Protocol document: